{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361137045751741952.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1007/s00535-009-0038-6"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/content/pdf/10.1007/s00535-009-0038-6.pdf"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/article/10.1007/s00535-009-0038-6/fulltext.html"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/content/pdf/10.1007/s00535-009-0038-6"}},{"identifier":{"@type":"PMID","@value":"19387534"}}],"dc:title":[{"@value":"Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B"}],"description":[{"notation":[{"@value":"The antiviral effect of adefovir dipivoxil (ADV) added to ongoing lamivudine (LAM) treatment for LAM-resistant chronic hepatitis B (CHB) differs among patients. We investigated clinical factors affecting the response to ADV therapy in LAM-resistant CHB.The subjects were 75 LAM-resistant CHB patients treated with ADV in addition to LAM. Virological response (VR) was defined as HBV DNA clearance (2.6 logcopies/ml) at 12 months after the start of ADV therapy. Clinical factors contributing to VR were examined by univariate and multivariate analyses.Lower HBV DNA at baseline and negative hepatitis B e antigen (HBeAg) were significant factors affecting VR in univariate analysis. In multivariate analysis, lower HBV DNA at baseline (P = 0.005), negative HBeAg (P = 0.009), and higher ALT (P = 0.036) were significant independent factors contributing to VR. In HBeAg-positive patients, HBV DNA clearance was more frequently observed during ADV therapy in patients with baseline HBV DNAor = 7.0 logcopies/ml than in those with baseline HBV DNA7.0 logcopies/ml. By contrast, the link of lower HBV DNA at baseline to better therapeutic response was not evident in HBeAg-negative patients.In ADV therapy added to ongoing LAM treatment for LAM-resistant CHB, lower baseline HBV DNA and negative HBeAg contributed to a better antiviral effect. Addition of ADV should be done promptly before marked increase in HBV DNA, especially in CHB patients showing LAM resistance positive for HBeAg."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381137045751741953","@type":"Researcher","foaf:name":[{"@value":"Nao Kurashige"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045751741957","@type":"Researcher","foaf:name":[{"@value":"Naoki Hiramatsu"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045751741825","@type":"Researcher","foaf:name":[{"@value":"Kazuyoshi Ohkawa"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045751741961","@type":"Researcher","foaf:name":[{"@value":"Takayuki Yakushijin"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045751741830","@type":"Researcher","foaf:name":[{"@value":"Shinichi Kiso"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045751741826","@type":"Researcher","foaf:name":[{"@value":"Tatsuya Kanto"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045751741832","@type":"Researcher","foaf:name":[{"@value":"Tetsuo Takehara"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045751741958","@type":"Researcher","foaf:name":[{"@value":"Akinori Kasahara"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045751741952","@type":"Researcher","foaf:name":[{"@value":"Yoshinori Doi"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045751741954","@type":"Researcher","foaf:name":[{"@value":"Akira Yamada"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045751741955","@type":"Researcher","foaf:name":[{"@value":"Masahide Oshita"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045751741960","@type":"Researcher","foaf:name":[{"@value":"Eiji Mita"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045751741829","@type":"Researcher","foaf:name":[{"@value":"Hideki Hagiwara"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045751741824","@type":"Researcher","foaf:name":[{"@value":"Toshihiko Nagase"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045751741831","@type":"Researcher","foaf:name":[{"@value":"Harumasa Yoshihara"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045751741827","@type":"Researcher","foaf:name":[{"@value":"Eijiro Hayashi"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045751741828","@type":"Researcher","foaf:name":[{"@value":"Yasuharu Imai"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045751741833","@type":"Researcher","foaf:name":[{"@value":"Michio Kato"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045751741956","@type":"Researcher","foaf:name":[{"@value":"Takeshi Kashihara"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045751741959","@type":"Researcher","foaf:name":[{"@value":"Norio Hayashi"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"09441174"},{"@type":"EISSN","@value":"14355922"}],"prism:publicationName":[{"@value":"Journal of Gastroenterology"}],"dc:publisher":[{"@value":"Springer Science and Business Media LLC"}],"prism:publicationDate":"2009-04-22","prism:volume":"44","prism:number":"6","prism:startingPage":"601","prism:endingPage":"607"},"reviewed":"false","dc:rights":["http://www.springer.com/tdm"],"url":[{"@id":"http://link.springer.com/content/pdf/10.1007/s00535-009-0038-6.pdf"},{"@id":"http://link.springer.com/article/10.1007/s00535-009-0038-6/fulltext.html"},{"@id":"http://link.springer.com/content/pdf/10.1007/s00535-009-0038-6"}],"createdAt":"2009-04-21","modifiedAt":"2023-05-24","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Gastroenterology","dc:title":"Gastroenterology"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846640256572160","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1007/s00535-009-0038-6"},{"@type":"OPENAIRE","@value":"doi_dedup___::e63c39c470fe372b3d21e3e5d83d5c9e"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_EElXUKGTy86kHnnXaP3hOzdGq1C"},{"@type":"CROSSREF","@value":"10.1007/s00535-011-0522-7_references_DOI_EElXUKGTy86kHnnXaP3hOzdGq1C"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_EElXUKGTy86kHnnXaP3hOzdGq1C"}]}